# Gilles Salles

Source: https://onco.cc/people/gilles-salles/  
OnCo record `gilles-salles` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.

## Summary

Gilles Salles led PRIMA, the trial showing two years of rituximab maintenance prolongs remission in follicular lymphoma, and co-chaired POLARIX, which showed polatuzumab vedotin plus R-CHP improves progression-free survival over R-CHOP in DLBCL, the first new first-line regimen in two decades. He led the French LYSA group before moving to MSKCC and co-led the tafasitamab and mosunetuzumab programmes.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: lymphoma; trialist; lysa
- Role: Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center
- Specialisms: Follicular lymphoma; Diffuse large B-cell lymphoma; Anti-CD20 antibodies; Cooperative-group trials

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Gilles_Salles
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD20](https://onco.cc/targets/cd20/)
- companies: [LYSA (The Lymphoma Study Association)](https://onco.cc/companies/lysa/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [POLARIX](https://onco.cc/trials/polarix/), [PRIMA](https://onco.cc/trials/prima-follicular/), [REMARC](https://onco.cc/trials/remarc/)
- key papers: [Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial](https://onco.cc/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/), [Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP](https://onco.cc/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/), [POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/), [Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial](https://onco.cc/key-papers/paper-prima-rituximab-maintenance-follicular-lancet-2011/), [Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study](https://onco.cc/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/gilles-salles.json